Abstract:You have accessJournal of UrologyBenign Prostatic Hyperlasia: Medical and Hormonal Therapy1 Apr 20131383 COMBINATION OF α-ADRENERGIC RECEPTOR BLOCKERS AND 5 α-REDUCTASE INHIBITORS FOR MODERATE TO SEVERE BENIGN PROSTATE HYPERPLASIA (BPH) PATIENTS WITH OR WITHOUT CONCOMITANT HYPERTENSION: RESULTS OF A PROSPECTIVE OBSERVATIONAL REAL-LIFE CLINICAL PRACTICE STUDY USING MULTICENTER REGISTRIES IN CHINA Ying-Hao Sun, Chuan-Liang Xu, Bo Yang, and Tie Zhou Ying-Hao SunYing-Hao Sun Shanghai, China, People's Republic of More articles by this author , Chuan-Liang XuChuan-Liang Xu Shanghai, China, People's Republic of More articles by this author , Bo YangBo Yang Shanghai, China, People's Republic of More articles by this author , and Tie ZhouTie Zhou Shanghai, China, People's Republic of More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2013.02.2737AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Both BPH and hypertension require long term medication therapy. We sought to study the efficacy of combination of α-adrenergic receptor blockers (AB) and 5 α-reductase inhibitors (5ARI) for moderate to severe BPH patients with or without concomitant hypertension by analyzing the data from our 1 year's prospective observational real-life clinical practice study using multicenter registries in China. METHODS The primary outcomes were the medication pattern and efficacy of the combination regimen as reflected by Prostate Volume (PV), maximum urinary flow rate (Qmax) and I-PSS. Serum Prostate-Specific Antigen (PSA) was also determined. RESULTS Among 2786 eligible patients, 68.92% (n=1920) patients were normotensive while 31.08% (n=866) were hypertensive and they were comparable in baseline characteristics except blood pressures (BP). At baseline, all the normotensive and hypertensive patients received AB and 5ARI combination regimen. At 12 months, 2675 patients are available, including 769 hypertensive ones. Qmax improvement was comparable in normotensive and hypertensive patients (P=0.3786). PV significantly declined in normotensive and hypertensive BPH patients from the baseline (P<0.0001 vs. baseline in both; P=0.5989, normotensive vs. hypertensive). I-PSS was improved greater in normotensive than in hypertensive BPH patients (P<0.0001), but both significantly higher than the baseline (P<0.0001). The combination regimen lowered mean systolic and diastolic BP by 7.3±14.05 and 3.1±9.95 mmHg, respectively, in hypertensive BPH patients (P<0.05 vs. baseline in both). CONCLUSIONS The AB and 5ARI combination regimen significantly improves BPH symptoms in both hypertensive and normotensive BPH patients and also has beneficial effect on BP in hypertensive BPH patients. Baseline characteristics of benign prostate hyperplasia patients with or without concomitant hypertension Characteristics All Patients Normotensive Hypertensive⁎ P value Systolic blood pressure (mmHg) 133.7±13.65 128.1±9.71 140.0±14.62 < 0.0001 Diastolic blood pressure (mmHg) 80.6±9.36 77.2±7.48 85.0±9.73 < 0.0001 PSA (ng/mL) 2.9±1.97 2. 9±1.95 2.8±2.01 0.3014 I-PSS 17.5± 5.38 17.5±5.38 17.4±5.36 0.6062 Prostate Volume (mL) 47.8±16.58 47.7±16.98 48.1±15.66 0.5881 Qmax (ml/sec) 11.6±3.55 11.7±3.49 11.5±3.67 0.2830 ⁎ Including patients with the hypertension history, under anti-hypertension treatment or newly diagnosed hypertension. Efficacy of combination treatment with α-adrenergic receptor blockers and 5α-reductase inhibitors for BPH patients with or without concomitant hypertension at 12 months Characteristics Normotensive Hypertensive P value Systolic blood pressure (mmHg) 7.4±9.93 7.3±14.05 0.8607 Diastolic blood pressure (mmHg) 2.7±8.16 3.1±9.95 0.5930 PSA (ng/mL) 0.8±1.66 0.8±2.65 0.8500 I-PSS 6.8±5.45 5.7±4.23 <0.0001 Prostate Volume (mL) 6.2±8.74 6.4±8.06 0.5989 Qmax (ml/sec) 2.4±2.75 2.5±3.34 0.3786 © 2013 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 189Issue 4SApril 2013Page: e566 Advertisement Copyright & Permissions© 2013 by American Urological Association Education and Research, Inc.MetricsAuthor Information Ying-Hao Sun Shanghai, China, People's Republic of More articles by this author Chuan-Liang Xu Shanghai, China, People's Republic of More articles by this author Bo Yang Shanghai, China, People's Republic of More articles by this author Tie Zhou Shanghai, China, People's Republic of More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...

Personalized Therapeutics of &Amp;alpha;1-Blockers In&nbsp;patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia

Personalized Therapeutics of Α1-Blockers In patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia

Role of Α1‐blockers in the Current Management of Hypertension

The Efficacy and Safety of Alpha-1 Blockers for Benign Prostatic Hyperplasia: an Overview of 15 Systematic Reviews

Adrenergic alpha-1 receptor antagonists in the treatment of lower urinary tract symptoms (LUTS) in women:a systematic review

[Progress in the Studies of Alpha1-Receptor Blocker for Benign Prostatic Hyperplasia].

Efficacy of Terazosin Therapy for Mild Hypertension Patients with Lower Urinary Tract Symptoms

The efficacy and safety of alpha-1 blockers for benign prostatic hyperplasia: an overview of 15 systematic reviews.

AB201. Two birds with one stone: α-blocker therapy on LUTS/BPH in men concomitant with mild hypertension

Efficacy Of Combined Amlodipine/Terazosin Therapy In Male Hypertensive Patients With Lower Urinary Tract Symptoms: A Randomized, Double-Blind Clinical Trial

The efficacy of combination therapy of tamsulosin and Qianlie Beixi capsule in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia

[Treatments of erectile dysfunction combined with lower urinary tract symptoms associated with benign prostatic hyperplasis].

Efficacy and Safety of Combined Therapy with Terazosin and Tolteradine for Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia: a Prospective Study

A Randomized Placebo-Controlled Study: Phellodendron Bawei Tablets Combined with Standard Management Can Improve Storage Symptoms, Sleep Quality, and Medication Compliance in Patients with Benign Prostatic Hyperplasia Compared to Placebo with Standard Management.

A multicenter prospective clinical study on the effectiveness and safety of terazosin in the treatment of Chinese benign prostatic hyperplasia patients

Hong Kong Geriatrics Society and Hong Kong Urological Association consensus on personalised management of male lower urinary tract symptoms in the era of multiple co-morbidities and polypharmacy.

A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia

Pharmacological treatment of lower urinary tract symptoms in benign prostatic hyperplasia: consequences on sexual function and possible endocrine effects

A Systematic Review and Meta-Analysis of the Efficacy and Safety of Tamsulosin Plus Tadalafil Compared With Tamsulosin Alone in Treating Males With Lower Urinary Tract Symptoms Secondary to Benign Prostrate Hyperplasia

Impact of Α-Blocker Therapy on Symptoms of Benign Prostatic Hyperplasia

Personalized Therapeutics of &Amp;alpha;1-Blockers In&amp;nbsp;patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia

Personalized Therapeutics of &Alpha;1-Blockers In&nbsp;patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia